查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1981389

乳癌筛检市场：按技术、年龄层、实施方法和最终用户划分－2026-2032年全球市场预测

Breast Cancer Screening Market by Technology, Age Group, Delivery Mode, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，乳癌筛检市场价值将达到 56.9 亿美元，到 2026 年将成长至 60.9 亿美元，到 2032 年将达到 97.5 亿美元，复合年增长率为 8.00%。

主要市场统计数据
基准年 2025 56.9亿美元
预计年份：2026年 60.9亿美元
预测年份 2032 97.5亿美元
复合年增长率 (%) 8.00%

乳癌筛检范式演变的全面概述，重点关注技术、政策、临床实践和以患者为中心的就医趋势。

乳癌筛检处于技术创新、临床指南、政策改革和不断变化的患者期​​望的交汇点，形成了一个动态环境，需要准确、循证的决策。影像技术、软体分析和医疗服务模式的进步正在重塑临床医生检测和管理早期疾病的方式。同时，法律规范和保险公司的优先事项也与关注价值、治疗结果和公平获取医疗服务的目标一致。此外，不断发展的宣传宣传活动和风险分层方法也推动了对更灵敏、更微创、更人性化的筛检途径的需求日益增长。

一项突破性的变革，加速了利用先进影像诊断、人工智慧整合、个人化筛检路径和分散式云端技术的护理模式的临床实施。

近年来，临床实践和市场动态发生了一系列变革性变化，重新定义了有效且公平的乳癌筛检。其中最显着的变化之一是容积成像和断层成像技术的快速临床应用。结合先进的后处理和解读流程，这些技术显着提高了病灶的可见性，并降低了复查率。影像技术的进步与人工智慧 (AI) 和机器学习演算法的成熟相辅相成，这些技术能够提昇放射科医师的诊疗水平，简化分流流程，并优化分散式网路中有限诊断资源的分配。

2025 年美国实施的关税对采购、製造地、供应链韧性和软体主导的临床连续性的累积影响。

美国2025年实施的关税政策产生了一系列累积效应，波及整个乳癌筛检价值链，影响筹资策略、供应商选择、製造地和临床部署计画。检测器、数位成像电子设备、专用泵浦和线圈以及整合到先进成像平台中的半导体组件等关键子系统的进口成本不断上涨，迫使供应商重新评估供应链冗余和组件采购。这些压力促使一些製造商加快区域生产和供应商多元化，同时压缩产品蓝图，并优先考虑模组级升级而非整系统更换。

实用的细分见解，阐明特定模式的趋势、特定年龄层的路径、交付方式的差异以及整个临床环境中最终用户的采用趋势。

了解乳癌筛检全过程中临床价值的产生点以及推广应用的障碍，关键在于掌握各个细分领域的趋势。技术细分能够清楚展现技术推广应用的轨迹。二维乳房X光乳房X光摄影仍然是基本的筛检手段，模拟和数位系统都仍在运作，但3D合成技术的应用正在不断增加，以提高在复杂乳房解剖结构中的检测精度。磁振造影（MRI）技术持续发展，根据患者的风险状况和临床适应症，造影增强通讯协定和非造影技术均被采用。分子乳房影像技术，包括乳房特异性伽玛成像和核子乳房摄影超音波发挥不同的作用，自动化超音波平台和携带式设备可用于互补的诊断目的，并扩大了门诊和社区医疗机构的诊疗范围。

对美洲、欧洲、中东和非洲以及亚太地区部署模式、还款环境和准入策略差异的关键区域见解。

区域差异正在影响乳癌筛检的技术应用、报销方式、人才引进以及医疗系统采用的营运模式。在美洲，尤其註重将先进的筛检能力整合到综合医疗网路和大规模诊断连锁机构中，同时，人们也越来越关注人工智慧驱动的影像解读平台，以管理庞大的患者群体并优化复检率。该地区的市场动态受到支付方模式的影响，这些模式奖励可验证的结果，而密集型肿瘤治疗计画则推动了对高风险族群高灵敏度检测方式的需求。

透过云端服务模式，从企业层面深入了解整合、模组化升级、临床证据产生和差异化。

乳癌筛检生态系统的竞争格局呈现出参与者多元化的特点，包括影像设备製造商、专业软体供应商、云端服务供应商、託管服务公司和临床服务网路。业界领导企业者透过整合硬体效能和进阶分析、提供强大的临床证据包以及降低整体拥有成本 (TCO) 的全生命週期服务能力来脱颖而出。医疗设备製造商与软体创新者之间的策略合作已被证明是加速人工智慧功能上市和透过合作研究弥合临床有效性差距的有效途径。

为产业领导者提供切实可行的建议，以加速采用、增强韧性，并向临床和支付方利害关係人展示价值。

产业领导者若想在乳癌筛检领域维持并扩大自身地位，应采取一系列切实可行的、以证据为基础的行动，使商业性目标与临床优先事项和营运实际情况相符。首先，应优先进行前瞻性、多中心且符合支付方要求的临床研究，以强有力的数据支持产品声明，证明其诊断效能、工作流程效率和后续临床影响。其次，应采用模组化产品和商业策略，使医疗服务供应商能够逐步升级软体分​​析、人工智慧模组和云端服务等功能，而无需完全更换成像系统。这有助于降低采用门槛，并维护客户关係。

采用严格的混合方法调查方法，结合第二手资料、相关人员检验和三角验证，对临床和商业性研究结果检验。

本分析的调查方法结合了定性和定量方法，以确保所得出的洞见具有稳健性、可重复性，并能为整个生态系统中的决策者提供参考。该方法首先进行全面的二手研究，参考同行评审文献、临床指南、监管文件、专利趋势和企业资讯披露，构建背景基础并识别关键的技术、监管和报销趋势。随后进行一手研究，包括与放射科医生、医院采购负责人、诊断中心管理人员、技术供应商、保险公司和临床研究人员等各类相关人员者进行结构化访谈和讨论，以检验假设、识别应用驱动因素并突出运营限制。

最终的综合分析将结合技术、临床和策略要求，指导相关人员在筛检实施和改善可及性方面取得显着成果。

总之，在技术进步、数据驱动型解决方案的兴起以及强调个人化医疗和可衡量结果的临床范式不断演进的推动下，乳癌筛检正在经历重大变革时期。高通量成像、人工智慧驱动的分析、多样化的服务模式以及对实证医学日益增长的期望，共同为价值链上的各相关人员创造了机会和挑战。专注于模组化、实证解决方案并投资于人才培养和供应链韧性的医疗服务提供者和供应商，将更有能力将创新转化为早期检测，并持续改善患者的治疗效果。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：乳癌筛检市场：依技术划分

  • 二维乳房X光摄影
    • 模拟
    • 数位的
  • 三维断层合成
  • 磁振造影
    • 造影的使用
    • 未使用造影
  • 分子乳房影像
    • 乳腺特异性伽马射线成像
    • 闪烁乳房X光摄影
  • 热成像
  • 超音波
    • 自动的
    • 携带式的

第九章：乳癌筛检市场：依年龄组别划分

  • 40-49岁
  • 50-69岁
  • 70岁以上
  • 40岁以下

第十章：乳癌筛检市场：依提供方式划分

  • 云
    • SaaS（Software as a Service）
    • 基于网路的
  • 现场

第十一章：乳癌筛检市场：依最终用户划分

  • 门诊部
  • 诊所
    • 基层医疗诊所
    • 专科诊所
  • 诊断中心
    • 连锁中心
    • 独立中心
  • 医院
    • 私立医院
    • 公立医院

第十二章乳癌筛检市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章乳癌筛检市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章乳癌筛检市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国乳癌筛检市场

第十六章：中国乳癌筛检市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Canon Medical Systems Corporation
  • Carestream Health, Inc.
  • Fujifilm Holdings Corporation
  • GE HealthCare
  • Hologic, Inc.
  • Konica Minolta, Inc.
  • Koninklijke Philips NV
  • NanoString Technologies, Inc.
  • NIRAMAI Health Analytix Private Limited
  • Novartis AG
  • Oncocyte Corporation
  • OncoStem Diagnostics Pvt. Ltd
  • Pfizer Inc.
  • Prelude Corporation
  • Quest Diagnostics Incorporated
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • Syantra Inc.
  • Vayyar Imaging, Ltd.
Product Code: MRR-521BAA36EB3C

The Breast Cancer Screening Market was valued at USD 5.69 billion in 2025 and is projected to grow to USD 6.09 billion in 2026, with a CAGR of 8.00%, reaching USD 9.75 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.69 billion
Estimated Year [2026] USD 6.09 billion
Forecast Year [2032] USD 9.75 billion
CAGR (%) 8.00%

Comprehensive introduction to evolving breast cancer screening paradigms highlighting technology, policy, clinical practice and patient-centric access dynamics

Breast cancer screening is at the intersection of technological innovation, clinical guidelines, policy reform, and shifting patient expectations, creating a dynamic environment that demands precise, evidence-based decision making. Advances in imaging modalities, software analytics, and care delivery models are reshaping how clinicians detect and manage early-stage disease, while regulatory frameworks and payer priorities are aligning to emphasize value, outcomes, and equitable access. Concurrently, evolving awareness campaigns and risk-stratified approaches have intensified demand for more sensitive, less invasive, and patient-friendly screening pathways.

Against this backdrop, the ecosystem that supports screening-manufacturers, hospital systems, ambulatory centers, diagnostic chains, software vendors, and payers-must reconcile competing pressures: the need to adopt high-performance technologies that improve diagnostic accuracy, the imperative to control costs and integrate with electronic workflows, and the requirement to demonstrate clinical utility and workforce readiness. Technological convergence, including the integration of advanced image reconstruction, multiplanar visualization, and intelligent algorithms, is accelerating the clinical uptake of modalities that were once confined to tertiary centers. Meanwhile, cloud-enabled delivery modes and software-as-a-service options are lowering barriers to deployment of advanced analytics and facilitating remote reading and second-opinion workflows.

The introduction sets the stage for a detailed exploration of transformational shifts, regulatory and trade headwinds, segmentation-specific dynamics, regional differentiation, competitive behavior, and pragmatic recommendations. It is designed to inform strategic planning by executives, clinical leaders, product teams, and procurement specialists seeking to position their organizations to capture clinical value, support scalable service models, and improve patient pathways without compromising on quality or compliance.

Pivotal transformative shifts accelerating clinical adoption of advanced imaging, AI integration, personalized screening pathways and distributed cloud-enabled care models

The past few years have produced a series of transformative shifts that are redefining what effective and equitable breast cancer screening looks like in clinical practice and in market dynamics. One of the most consequential shifts is the rapid clinical adoption of volumetric and tomographic imaging techniques, which when combined with sophisticated post-processing and reading workflows, have materially improved lesion conspicuity and reduced recall rates. These imaging advances are complemented by the maturation of artificial intelligence and machine learning algorithms that augment radiologist performance, streamline triage pathways, and optimize the allocation of scarce diagnostic expertise across distributed networks.

Another foundational shift is the movement toward personalized, risk-based screening pathways. Rather than one-size-fits-all intervals and modalities, screening programs are increasingly calibrated using a combination of clinical risk factors, genetic predispositions, and prior imaging history. This has catalyzed interest in adjunctive modalities for selected cohorts, including contrast-enhanced MRI for high-risk individuals and molecular imaging techniques for dense-breast populations where traditional mammography has limitations. In parallel, delivery models are evolving: cloud-enabled platforms and software-as-a-service offerings have accelerated the decentralization of advanced analytics and enabled remote interpretation, while automated and point-of-care hardware variants are expanding access in ambulatory centers and community clinics.

Workforce transformation and clinical training are also reshaping the landscape. As imaging complexity grows, so does the need for multidisciplinary collaboration, standardized reporting, and robust quality assurance programs. Regulatory emphasis on interoperability, data privacy, and evidence of clinical benefit has heightened the bar for new product adoption, incentivizing vendors to generate stronger real-world evidence and to engage payers earlier. Collectively, these shifts are creating a screening ecosystem that is more technology-driven, more patient-centric, and more focused on demonstrable outcomes than in previous eras.

Cumulative implications of United States tariffs enacted in 2025 on procurement, manufacturing footprints, supply chain resilience and software-led clinical continuity

The imposition of tariffs by the United States in 2025 has introduced a set of cumulative effects that are reverberating across the breast cancer screening value chain, influencing procurement strategies, vendor sourcing, manufacturing footprints, and clinical adoption timelines. Increased import costs for key subsystems, such as detectors, digital acquisition electronics, specialized pumps and coils, and the semiconductor components embedded in advanced imaging platforms, have pressured equipment vendors to rethink supply chain redundancy and component sourcing. These pressures have incentivized some manufacturers to accelerate regional manufacturing or supplier diversification while compressing product roadmaps to prioritize modular upgrades over full-system replacements.

Procurement decision-makers within hospitals, diagnostic centers, and ambulatory care settings have responded by extending equipment life cycles where clinically feasible and by negotiating multi-year service and upgrade agreements that can mitigate near-term capital cost inflation. At the same time, smaller and independent diagnostic operators have sought alternative delivery models, shifting demand toward cloud-based software subscriptions and managed services that reduce upfront capital exposure. The tariffs have also amplified the importance of software-driven diagnostic enhancements that can be deployed on existing hardware platforms, enabling providers to extract incremental clinical value without undertaking full equipment replacements.

Regulatory and payer stakeholders have become more attentive to the downstream implications of supply chain disruptions on access to care and the consistency of screening programs. In response, some health systems have prioritized investments in clinical training, cross-platform compatibility, and contingency stocking of critical spare parts to preserve service continuity. Finally, the macroeconomic signal sent by tariffs has affected investor and partnership behavior, prompting some vendors to reassess geographic expansion strategies and to seek manufacturing collaborations in markets with more favorable trade terms. The net effect is a reconfiguration of strategic priorities across manufacturers, service providers, and health systems that emphasizes resilience, software-led differentiation, and flexible procurement models.

Actionable segmentation insights revealing modality-specific trajectories, age-tailored pathways, delivery-mode differentiation and end-user adoption dynamics across care settings

Segment-specific dynamics are crucial for understanding where clinical value is created and where adoption friction persists across the breast cancer screening continuum. Technology segmentation reveals distinct adoption trajectories: two-dimensional mammography remains a foundational screening modality with analog and digital variants still in operation alongside the increasing uptake of three-dimensional tomosynthesis for improved detection in complex breast anatomy. Magnetic resonance imaging continues to diversify with contrast-enhanced protocols and non-contrast techniques being deployed according to patient risk profiles and clinical indications. Molecular breast imaging, including breast-specific gamma imaging and scintimammography, is gaining selective traction as an adjunct in cases of dense tissue where traditional x-ray-based modalities are challenged. Thermography and ultrasound modalities present differentiated roles; automated ultrasound platforms and handheld devices serve complementary diagnostic purposes and extend access in ambulatory and community settings.

Age group segmentation underscores the need for differentiated pathways: younger cohorts and those under forty often require diagnostic-focused imaging due to symptom-driven evaluation and genetic risk, while middle-aged groups typically represent the core screening population with modality selection influenced by breast density and prior imaging history. Older cohorts may face different trade-offs between sensitivity and the risks associated with overdiagnosis, necessitating nuanced shared decision-making processes. Delivery-mode segmentation is shaping deployment and operational models: on-premise solutions remain essential for high-throughput imaging centers and integrated hospital systems, whereas cloud-based offerings, including software-as-a-service and web-based platforms, are enabling distributed reading workflows, centralized quality control, and incremental adoption of advanced analytics without significant capital outlay. End-user segmentation highlights the different adoption drivers across care settings: ambulatory care centers, clinics-both primary care and specialty clinics-diagnostic centers, whether chain or independent, and hospitals, both public and private, each operate under distinct procurement cycles, clinical governance structures, and reimbursement environments. Understanding these segmentation layers in combination is essential for designing product strategies, clinical evidence generation plans, and go-to-market approaches that align with the needs and constraints of each stakeholder group.

Key regional insights on differentiated adoption patterns, reimbursement environments and access strategies across Americas, EMEA and Asia-Pacific

Regional differentiation influences technology adoption, reimbursement approaches, workforce availability, and the operational models that health systems deploy for breast cancer screening. In the Americas, there is a pronounced emphasis on consolidating advanced screening capabilities within integrated delivery networks and large diagnostic chains, coupled with growing interest in deploying AI-enabled reading platforms to manage high patient volumes and optimize recall rates. Market dynamics in this region are shaped by payer models that reward demonstrable outcomes and by centralized oncology programs that drive demand for high-sensitivity modalities in high-risk populations.

The Europe, Middle East & Africa region presents a heterogeneous landscape where regulatory standards, public screening program structures, and resource availability vary widely across national jurisdictions. In parts of this region, organized population-based screening programs and universal coverage models have accelerated the adoption of standardized protocols and quality assurance frameworks, while in others, infrastructure and workforce constraints have fostered innovation in portable, lower-cost modalities and tele-radiology services that bridge gaps in access.

Asia-Pacific demonstrates a blend of high-capacity tertiary centers equipped with the latest imaging platforms and rapidly expanding community-level diagnostic services that prioritize accessibility and cost-effectiveness. In several markets, public health initiatives and private sector expansion are simultaneously increasing screening uptake, which in turn has stimulated demand for cloud-enabled workflows, AI-driven triage tools, and scalable ultrasound solutions that can be deployed in both urban and semi-urban contexts. Across regions, the balance between centralized specialist services and decentralized community access will continue to shape investment priorities and partnership models.

Strategic company-level insights on differentiation through integration, modular upgradability, clinical evidence generation and cloud-enabled service models

Competitive dynamics in the breast cancer screening ecosystem are defined by a diverse set of participants spanning imaging equipment manufacturers, specialized software vendors, cloud service providers, managed service firms, and clinical service networks. Leaders are differentiating through integrated solutions that combine hardware performance with advanced analytics, robust clinical evidence packages, and lifecycle service capabilities that reduce total cost of ownership. Strategic partnerships between device manufacturers and software innovators have become an effective route to accelerate time-to-market for AI-enabled features and to bridge clinical validation gaps through collaborative studies.

Another important trend among companies is the emphasis on modularity and upgradability, which allows customers to incrementally adopt advanced capabilities while preserving existing capital investments. This approach has been particularly attractive in environments where capital budgets are constrained or where tariff-related procurement volatility has heightened the appeal of software-driven clinical improvement. Service providers and managed-read vendors are capitalizing on cloud delivery and subscription models to offer scalable reading capacity, centralized quality assurance, and performance analytics that are valuable to both large hospital networks and independent diagnostic centers.

Finally, corporate strategies are increasingly focused on demonstrating real-world clinical impact and payer-relevant outcomes. Companies that invest in prospective clinical studies, health-economic analyses, and collaborative evidence generation with leading clinical centers are better positioned to influence guideline development and payer coverage decisions. As a result, a bifurcation is emerging between firms that emphasize incremental feature improvements and those that pursue deeper clinical validation and integrated care pathways as a route to sustained differentiation.

Practical and actionable recommendations for industry leaders to accelerate adoption, build resilience, and demonstrate clinical and payer-relevant value

Industry leaders seeking to maintain and grow their positions in the breast cancer screening arena should pursue a set of pragmatic, evidence-driven actions that align commercial objectives with clinical priorities and operational realities. First, prioritize clinical evidence generation that is prospective, multi-center, and aligned to payer endpoints so that product claims are supported by robust data demonstrating diagnostic performance, workflow efficiency, and downstream clinical impact. Second, adopt a modular product and commercial strategy that enables providers to incrementally upgrade capabilities-software analytics, AI modules, and cloud services-without requiring wholesale replacement of imaging systems, thereby lowering adoption barriers and preserving customer relationships.

Third, strengthen supply chain resilience by diversifying component sourcing, exploring regional manufacturing partnerships, and developing service models that minimize downtime and ensure continuity of diagnostic services during disruptions. Fourth, invest in training and change management programs that support radiologists, technologists, and referring clinicians in integrating new modalities and AI-assisted workflows; such investments accelerate adoption, improve diagnostic consistency, and enhance patient satisfaction. Fifth, actively engage with regulatory bodies, guideline committees, and payers to communicate real-world evidence and to shape reimbursement paradigms that reward value and outcomes rather than procedural volume. Sixth, pursue strategic collaborations across the ecosystem-academic centers, specialty clinics, chains of diagnostic centers, and technology partners-to co-develop clinical pathways, pilot new care models, and validate value propositions in representative clinical environments. By executing on these priorities, industry leaders can reduce friction in adoption, demonstrate measurable clinical benefit, and position their offerings for sustainable uptake across diverse care settings.

Rigorous mixed-methods research methodology combining secondary evidence, stakeholder interviews and triangulation to validate clinical and commercial insights

The research methodology underpinning this analysis combines qualitative and quantitative approaches to ensure that insights are robust, replicable, and relevant to decision-makers across the ecosystem. The approach begins with comprehensive secondary research drawing from peer-reviewed literature, clinical guidelines, regulatory filings, patent landscapes, and company disclosures to build a contextual foundation and identify key technology, regulatory, and reimbursement trends. This is followed by primary research, including structured interviews and consultations with a cross-section of stakeholders such as radiologists, hospital procurement officers, diagnostic center managers, technology vendors, payers, and clinical investigators, to validate assumptions, uncover adoption drivers, and surface operational constraints.

Data triangulation is applied to reconcile diverse inputs and to ensure internal consistency; clinical claims and product capabilities are cross-referenced with published studies and expert commentary. Segmentation frameworks are developed and iteratively refined through stakeholder validation to reflect real-world decision processes across technology, age cohorts, delivery modes, and end-user types. Quality assurance includes methodological audits, peer review by subject-matter experts, and sensitivity checks on key qualitative inferences. Finally, findings are synthesized into actionable narratives and strategic imperatives that are designed to support procurement decisions, product development roadmaps, clinical adoption strategies, and policy engagement initiatives.

Concluding synthesis that integrates technological, clinical and strategic imperatives to guide stakeholders toward impactful screening adoption and access improvements

In conclusion, breast cancer screening is undergoing a period of substantive transformation driven by technological advancement, the ascendancy of data-driven solutions, and evolving clinical paradigms that emphasize personalized care and measurable outcomes. The confluence of volumetric imaging, AI-enabled analytics, diversified delivery models, and increasingly sophisticated evidence expectations has created both opportunities and challenges for stakeholders across the value chain. Providers and vendors that align around modular, evidence-backed solutions and invest in workforce readiness and supply chain resilience will be best positioned to translate innovation into sustained improvements in early detection and patient outcomes.

Looking forward, the strategic focus should remain on integrating new capabilities within existing clinical workflows, demonstrating comparative clinical value in relevant patient cohorts, and crafting procurement and reimbursement narratives that reflect long-term outcomes and system-level efficiencies. By prioritizing these elements-clinical validation, flexible deployment, regional sensitivity, and pragmatic engagement with payers and policymakers-stakeholders can navigate trade headwinds, scale access to high-performance screening modalities, and ultimately contribute to earlier detection and better patient trajectories across diverse health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Breast Cancer Screening Market, by Technology

  • 8.1. 2D Mammography
    • 8.1.1. Analog
    • 8.1.2. Digital
  • 8.2. 3D Tomosynthesis
  • 8.3. Magnetic Resonance Imaging
    • 8.3.1. Contrast Enhanced
    • 8.3.2. Non Contrast
  • 8.4. Molecular Breast Imaging
    • 8.4.1. Breast Specific Gamma Imaging
    • 8.4.2. Scintimammography
  • 8.5. Thermography
  • 8.6. Ultrasound
    • 8.6.1. Automated
    • 8.6.2. Handheld

9. Breast Cancer Screening Market, by Age Group

  • 9.1. 40 To 49
  • 9.2. 50 To 69
  • 9.3. 70 And Above
  • 9.4. Under 40

10. Breast Cancer Screening Market, by Delivery Mode

  • 10.1. Cloud
    • 10.1.1. Software As A Service
    • 10.1.2. Web Based
  • 10.2. On Premise

11. Breast Cancer Screening Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Clinics
    • 11.2.1. Primary Care Clinics
    • 11.2.2. Specialty Clinics
  • 11.3. Diagnostic Centers
    • 11.3.1. Chain Centers
    • 11.3.2. Independent Centers
  • 11.4. Hospitals
    • 11.4.1. Private Hospitals
    • 11.4.2. Public Hospitals

12. Breast Cancer Screening Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Breast Cancer Screening Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Breast Cancer Screening Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Breast Cancer Screening Market

16. China Breast Cancer Screening Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Canon Medical Systems Corporation
  • 17.6. Carestream Health, Inc.
  • 17.7. Fujifilm Holdings Corporation
  • 17.8. GE HealthCare
  • 17.9. Hologic, Inc.
  • 17.10. Konica Minolta, Inc.
  • 17.11. Koninklijke Philips N.V.
  • 17.12. NanoString Technologies, Inc.
  • 17.13. NIRAMAI Health Analytix Private Limited
  • 17.14. Novartis AG
  • 17.15. Oncocyte Corporation
  • 17.16. OncoStem Diagnostics Pvt. Ltd
  • 17.17. Pfizer Inc.
  • 17.18. Prelude Corporation
  • 17.19. Quest Diagnostics Incorporated
  • 17.20. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 17.21. Shimadzu Corporation
  • 17.22. Siemens Healthineers AG
  • 17.23. Syantra Inc.
  • 17.24. Vayyar Imaging, Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BREAST CANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BREAST CANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BREAST CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BREAST CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ANALOG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ANALOG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ANALOG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 3D TOMOSYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 3D TOMOSYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 3D TOMOSYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CONTRAST ENHANCED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CONTRAST ENHANCED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CONTRAST ENHANCED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY NON CONTRAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY NON CONTRAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY NON CONTRAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST SPECIFIC GAMMA IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST SPECIFIC GAMMA IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST SPECIFIC GAMMA IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCINTIMAMMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCINTIMAMMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCINTIMAMMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUTOMATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUTOMATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HANDHELD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HANDHELD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HANDHELD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 40 TO 49, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 40 TO 49, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 40 TO 49, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 50 TO 69, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 50 TO 69, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 50 TO 69, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 70 AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 70 AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 70 AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY UNDER 40, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY UNDER 40, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY UNDER 40, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SOFTWARE AS A SERVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SOFTWARE AS A SERVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SOFTWARE AS A SERVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY WEB BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY WEB BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY WEB BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ON PREMISE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CHAIN CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CHAIN CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CHAIN CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INDEPENDENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INDEPENDENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INDEPENDENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 229. GCC BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. GCC BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 232. GCC BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 233. GCC BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 234. GCC BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 235. GCC BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. GCC BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 238. GCC BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. GCC BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 240. GCC BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 268. G7 BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 269. G7 BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. G7 BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 271. G7 BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 272. G7 BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 273. G7 BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 274. G7 BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 275. G7 BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 276. G7 BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 277. G7 BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. G7 BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 279. G7 BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 280. G7 BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 281. NATO BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. NATO BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. NATO BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 284. NATO BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 285. NATO BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 286. NATO BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 287. NATO BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 288. NATO BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 289. NATO BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 290. NATO BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. NATO BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 292. NATO BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 293. NATO BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA BREAST CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)